文献速递血脂与心血管预防

Inclisiran 治疗高胆固醇血症的安全性:7 项临床试验汇总分析

Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

该事后分析汇总 ORION-1、-3、-5、-9、-10、-11 及正在进行的 ORION-8 试验,比较 inclisiran 300 mg 与安慰剂的安全性。inclisiran 组 3576 例暴露最长 6 年,安慰剂组 1968 例暴露最长 1.5 年;两组严重或导致停药的治疗中出现的不良事件、肝肌肾事件、新发糖尿病及肌酸激酶或肌酐升高发生率相当,未发现新安全信号。

要点

  • inclisiran 长期治疗未发现新的安全性信号,总体耐受良好。
  • 严重不良事件、停药、肝肌肾事件及新发糖尿病发生率与安慰剂相当。
  • 治疗诱导的抗药抗体少见(4.6%),持续性更少(1.4%),未增加停药或严重不良事件。

核心结论

  • 长期使用 inclisiran 在多样化人群中耐受良好,未发现新的安全性信号,支持其用于血脂异常患者的安全性。

研究设计与样本

  • 事后分析汇总 6 项已完成试验(ORION-1、-3、-5、-9、-10、-11)和 1 项正在进行试验(ORION-8)。
  • inclisiran 组 3576 例接受 300 mg inclisiran sodium,暴露最长 6 年,共 9982.1 患者年。
  • 安慰剂组 1968 例,暴露最长 1.5 年,共 2647.7 患者年。

主要发现

  • Kaplan-Meier 分析显示,至 1.5 年时两组严重或导致停药的治疗中出现的不良事件、肝肌肾事件、新发糖尿病及肌酸激酶或肌酐升高的累积发生率相当。
  • inclisiran 组在 1.5 年后的上述事件趋势与安慰剂组相似。
  • 该期间 inclisiran 组以治疗中出现的不良事件报告的 major cardiovascular events 数值上更少。
  • 治疗诱导的抗药抗体发生率为 4.6%,其中持续性仅 1.4%,且与导致停药的治疗中出现的不良事件或严重治疗中出现的不良事件发生率增加无关。

临床怎么用

  • 对于高胆固醇血症患者,长期使用 inclisiran 未显示新的安全性担忧,可支持其临床应用的耐受性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inclisiran is a small interfering RNA agent to lower low-density lipoprotein cholesterol. OBJECTIVES: The purpose of this study was to provide reliable evidence to date on the long-term safety profile of inclisiran. METHODS: This post hoc analysis comprised patients treated with 300 mg inclisiran sodium or placebo in the completed (ORION-1, -3, -5, -9, -10, and -11) and ongoing (ORION-8) trials. Exposure-adjusted incidence rates and Kaplan-Meier estimates of cumulative incidence of reported treatment-emergent adverse events (TEAE), abnormal laboratory measurements, and incidence of antidrug antibodies were analyzed. RESULTS: This analysis included 3,576 patients treated with inclisiran for up to 6 years and 1,968 patients treated with placebo for up to 1.5 years, with 9,982.1 and 2,647.7 patient-years of exposure, respectively. Baseline characteristics were balanced between groups. Kaplan-Meier analyses showed that TEAEs that were serious or led to discontinuation; hepatic, muscle, and kidney events; incident diabetes; and elevations of creatine kinase or creatinine accrued at a comparable rate between groups for up to 1.5 years, with similar trends continuing for inclisiran beyond this period. Numerically fewer major cardiovascular events reported as TEAEs occurred with inclisiran during this period. Treatment-induced antidrug antibodies were uncommon with inclisiran (4.6%), with few of these persistent (1.4%) and not associated with greater incidence of TEAEs leading to study drug discontinuation or serious TEAEs. CONCLUSIONS: Long-term treatment with inclisiran was well tolerated in a diverse population, without new safety signals, supporting the safety of inclisiran in patients with dyslipidemia.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Wright RS, Koenig W, Landmesser U, et al. Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials. J Am Coll Cardiol. 2023. PMID: 38057066. doi:10.1016/j.jacc.2023.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。